North America Point of Care Testing Market Overview (2024–2035)
The North American Point of Care Testing (POCT) market is projected to grow from USD 15.4 billion in 2024 to USD 30.5 billion by 2035, at a CAGR of 6.4% between 2025 and 2035. POCT encompasses diagnostic tests performed near the patient, offering rapid results that enhance clinical decision-making and patient care.
Market Dynamics
Key Drivers:
Increasing prevalence of chronic diseases like diabetes and cardiovascular conditions.
Rising demand for fast, reliable diagnostics in emergency and acute care settings.
Technological advancements, such as biosensors and mobile connectivity, improving usability and accuracy.
Technological Innovations:
Request sectional data :https://www.metatechinsights.com/industry-insights/north-america-point-of-care-testing-market-
High-accuracy miniaturized devices (accuracy rates exceeding 90%).
Mobile health integration enabling real-time monitoring and faster clinical decisions.
Development of specialized POCT tools for diseases like diabetes and infectious conditions.
Challenges:
Financial limitations in smaller clinics hinder adoption of advanced POCT devices.
Reimbursement challenges, affecting affordability and accessibility.
Regional Insights
United States:
The largest market, driven by advanced healthcare infrastructure and a high prevalence of diabetes (34.2 million adults).
Urban areas like New York and Los Angeles lead in adoption, while rural areas increasingly integrate POCT for better accessibility.
Canada:
The fastest-growing market, supported by government healthcare initiatives.
High demand for testing solutions for diabetes, asthma, and COPD, driven by rising disease prevalence.
Segment Analysis
By Product Type: Blood glucose monitoring dominates, fueled by diabetes management needs. Infectious disease and cardiac testing are also significant contributors.
By Sample Type: Blood samples lead, being vital for diverse diagnostic purposes and rapid clinical decisions.
Competitive Landscape
Top players include Abbott Laboratories, Roche Diagnostics, and Quidel Corporation. Innovations like Abbott’s Afinion 2 Analyzer and Quidel’s Sofia 2 SARS Antigen FIA highlight the competitive edge and focus on improving testing efficiency.
Future Outlook
The market’s expansion will be driven by technological innovation, preventive care initiatives, and telehealth integration. These trends will improve diagnostics accessibility across urban and remote areas, positioning POCT as a cornerstone of modern healthcare in North America.
